Literature DB >> 8276238

The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.

N P Pavletich1, K A Chambers, C O Pabo.   

Abstract

Mutations in the p53 tumor suppressor gene are the most commonly observed genetic alterations in human cancer. The majority of these mutations occur in the conserved central portion of the gene, but there has been little information about the function of this region. Using proteolytic digestion of the 393-amino-acid human p53 protein, we have identified a 191-amino-acid protease-resistant fragment (residues 102-292) that corresponds to the central portion of p53, and we show that this core fragment is the sequence-specific DNA-binding domain of the protein. DNA binding is inhibited by metal chelating agents, and we find that the core domain contains zinc. Proteolytic digests also reveal a 53-amino-acid carboxy-terminal domain which we show to be the tetramerization domain of p53.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8276238     DOI: 10.1101/gad.7.12b.2556

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  152 in total

1.  An ATP/ADP-dependent molecular switch regulates the stability of p53-DNA complexes.

Authors:  A L Okorokov; J Milner
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27.

Authors:  P Ianakiev; M W Kilpatrick; I Toudjarska; D Basel; P Beighton; P Tsipouras
Journal:  Am J Hum Genet       Date:  2000-06-05       Impact factor: 11.025

3.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.

Authors:  R Zhao; K Gish; M Murphy; Y Yin; D Notterman; W H Hoffman; E Tom; D H Mack; A J Levine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

4.  Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding.

Authors:  F Janus; N Albrechtsen; U Knippschild; L Wiesmüller; F Grosse; W Deppert
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

5.  MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins.

Authors:  E Kobet; X Zeng; Y Zhu; D Keller; H Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

6.  Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Authors:  M S Rodriguez; J M Desterro; S Lain; D P Lane; R T Hay
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

7.  Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo.

Authors:  M D Kaeser; R D Iggo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

8.  Role of tumor suppressor p53 domains in selective binding to supercoiled DNA.

Authors:  Marie Brázdová; Jan Palecek; Dmitry I Cherny; Sabina Billová; Miroslav Fojta; Petr Pecinka; Borivoj Vojtesek; Thomas M Jovin; Emil Palecek
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

9.  Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin.

Authors:  Z P Ren; A Ahmadian; F Pontén; M Nistér; C Berg; J Lundeberg; M Uhlén; J Pontén
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

10.  The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.

Authors:  Shelley Macaulay; Quintin Clive Goodyear; Mia Kruger; Wenlong Chen; Fahmida Essop; Amanda Krause
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.